A phase II trial of sorafenib (SOR) in patients (pts) with advanced cholangiocarcinoma (CC)
Cristina Dealis, PierFranco Conte(University of Padua), Giovanna Cavazzini(University of Padua), C. Boni(Ospedale Santa Maria), S. Zironi, N. Malavasi, Federica Bertolini, Gabriele Luppi(University of Modena and Reggio Emilia), Enrico Aitini, Maria Banzi(Azienda Ospedaliera S.Maria)
Cited by 7
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k